BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:44 PM
Apr 21, 2009
 |  BC Extra  |  Company News

Merck delays migraine compound, reports earnings

Merck & Co. Inc. (NYSE:MRK) said it will not submit an NDA for telcagepant ( MK-0974) for migraine this year, as was planned. The company said data from a Phase IIa trial...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >